Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy
Recent Publication
A current review article from the Divisionof Molecular Oncology and Haematology in cooperation with the University Hospital Krems shows how new therapies can specifically break down certain control proteins in cancer cells - so-called transcription factors. These proteins are often disrupted in multiple myeloma and contribute to the disease spreading or treatments not working. Drugs such as IMiDs use the cell's own “waste disposer” (cereblon) to break down these harmful proteins. New active substances such as CELMoDs and PROTACs are based on this principle and could significantly improve the treatment of multiple myeloma in the future.
Meli, R., Aksoy, O., Vallet, S., Slade, D., & Podar, K. (2025). Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy. Expert Opinion on Therapeutic Targets. Advance online publication. https://doi.org/10.1080/14728222.2025.2482557
Dr. Rajeshwari Meli
Scientific Staff (PostDoc)
Department of Molecular Oncology and Hematology
Dr. Osman Aksoy
Scientific Staff (PostDoc)
Department of Molecular Oncology and Hematology
OÄ PD Dr. Sonia Vallet
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
OA Univ.-Prof. Mag. DDr. Klaus Podar
Head of
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)